Merck KGaA confident on 2018 despite '2017 challenges'

Bosses at German life sciences and pharma company Merck KGaA told analysts and investors at its 2017 Capital Markets Day on Thursday that it was confident on achieving its overarching objectives for 2018.

There were admissions, however, that the current year was proving challenging. The company has also said that it will decide by the end of this year whether it will submit its multiple sclerosis drug Mavenclad (cladribine) for regulatory review in the USA.